Aug 01, 2019 7:15am EDT Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
Jul 29, 2019 4:05pm EDT Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
Jul 25, 2019 8:00am EDT Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
Jul 22, 2019 8:00am EDT Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
Jul 18, 2019 8:00am EDT Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
Jun 27, 2019 8:00am EDT Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
May 15, 2019 8:00am EDT Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
May 06, 2019 7:00am EDT Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
May 02, 2019 7:00am EDT Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting
